wire - news in brief

« BACK

Business/Economics



Results 1 - 50 of 361.
1 2 3 4 5 8 Next »

Medicine/Pharmacology - Business/Economics
21.08.2017
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission Ā  KAF156 is first compound fro
Environment/Sustainable Development - Business/Economics
16.08.2017
Online campaign against invasive plants
Online campaign against invasive plants
Neophytes - invasive plants that are alien to the region - are a huge burden on the public purse. The ETH spin-off "In-Finitude" has set up a new online platform right on time for the growing season.
Business/Economics - Administration/Government
15.08.2017
The smart grid analysts
The smart grid analysts
ETH spin-off Adaptricity has developed a piece of software that can be used to analyse the increasingly intelligent power grids.
Medicine/Pharmacology - Business/Economics
25.07.2017
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%,
Business/Economics - Medicine/Pharmacology
18.07.2017
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Net sales in line with prior year (0% cc , -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (U
Computer Science/Telecom - Business/Economics
27.06.2017
More security in cyberspace
More security in cyberspace
At yesterday's Cyber Risks Summit at ETH Zurich, international experts discussed and presented the latest scientific and technological approaches for effectively protecting society from the dangers of cyberspace.
Earth Sciences - Business/Economics
16.06.2017
A new view of the world
A new view of the world
The Swiss World Atlas has been published in a completely revised new edition. In addition to the usual topographic relief maps, it also contains maps on current global issues such as the environment, energy and conflicts. Since 1910, the Swiss World Atlas has accompanied generations of secondary school pupils through their geography lessons, conveying not only a comprehensive picture of the earth, but also the specific geography of Switzerland.
Physics/Materials Science - Business/Economics
14.06.2017
From the garage to the world
In 1999, PSI researchers founded the spin-off firm SwissNeutronics. Today the company has a staff of 15, sells high-precision components to research institutions all over the world, and still is based in the small town of Klingnau - not far from PSI.
Medicine/Pharmacology - Business/Economics
09.06.2017
Hybrid membrane creates a stir on the global market
Hybrid membrane creates a stir on the global market
ETH Professor Raffaele Mezzenga and his senior researcher Sreenath Bolisetty have developed a filter membrane that efficiently removes heavy metals and other toxic substances from water. Strong demand for the new technology has encouraged them to set up a new ETH spin-off, BluAct Technologies. The news story made a big splash: in January 2016 ETH researchers Professor Raffaele Mezzenga and his senior researcher Sreenath Bolisetty published a study about an innovative type of membrane developed in their laboratory.
Business/Economics - Environment/Sustainable Development
02.06.2017
Emissions trading scheme: acquisition of aviation data in 2018
Bern, 02.06.2017 - The integration of greenhouse gas emissions from the aviation sector into the emissions trading scheme (ETS) is a necessary step in order to link the Swiss and European schemes.
Medicine/Pharmacology - Business/Economics
31.05.2017
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 Building depth across key therapeutic areas wi
Physics/Materials Science - Business/Economics
29.05.2017
To the limits of the feasible
First, the engineers and the physicists had to find each other. Then, however, the company Daetwyler built the undulators for the free-electron X-ray laser SwissFEL of the Paul Scherrer Institute PSI as precisely as was possible: to one-tenth of the width of a hair.
Environment/Sustainable Development - Business/Economics
26.05.2017
Natural disasters and climate-related risks: Switzerland appeals for closer links between disaster risk reduction, climate change and development cooperation
Natural disasters and climate-related risks: Switzerland appeals for closer links between disaster risk reduction, climate change and development cooperation Bern, 26.05.2017 - Natural disasters and climate-related risks threaten to reverse hard-won gains in development.
Medicine/Pharmacology - Business/Economics
04.05.2017
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH   Conatus has initiated the Phase IIb ENCORE-LF clinical trial with emricasan in NASH.
Environment/Sustainable Development - Business/Economics
27.04.2017
Publication of Annual and Sustainability Reports
Publication of Annual and Sustainability Reports
The ETH Zurich 2016 Annual Report provides an overview of the most important achievements, developments and events at the University over the past year, and is published alongside the 2015/2016 Sustainability Report.
Medicine/Pharmacology - Business/Economics
26.04.2017
Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma Now available in the UK, G
Business/Economics - Medicine/Pharmacology
25.04.2017
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued Net sales grew 2% (cc, -1
Computer Science/Telecom - Business/Economics
20.04.2017
Sounds provide a safer login
Sounds provide a safer login
A start-up formed by a group of IT specialists at ETH has come up with a simple and user-friendly way to enhance network security.
Medicine/Pharmacology - Business/Economics
18.04.2017
Novartis expands development programs for NASH through clinical collaboration with Allergan
Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive  form of non-alcoholic fatty liver disease   There are currently no ap
Business/Economics
13.04.2017
Medicine/Pharmacology - Business/Economics
06.04.2017
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet medic
Physics/Materials Science - Business/Economics
28.03.2017
Dominique Derome new Head of Laboratory
Dominique Derome new Head of Laboratory
On 1 April 2017, Dominique Derome will become the new Head of the Laboratory for Multiscale Studies in Building Physics.
Earth Sciences - Business/Economics
27.03.2017
Archival photos offer research value
Archival photos offer research value
A crowdmapping project developed by EPFL and HEIG-VD gives volunteers the chance to compare the Switzerland of the 1960s with that of today through archival photos.
Medicine/Pharmacology - Business/Economics
26.03.2017
Business/Economics - Environment/Sustainable Development
03.03.2017
Environmental aspects in financial market policy: Federal Council is informed of progress made
Bern, 03.03.2017 - Sustainability is important also for the financial markets.
Business/Economics - Careers/Employment
28.02.2017
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
Shareholders approve 20 th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow   Dr. Joer
Environment/Sustainable Development - Business/Economics
22.02.2017
2nd edition of the Swiss Cleantech
2nd edition of the Swiss Cleantech
Six years after it first appeared, the second edition of the Swiss Cleantech Report was unveiled today at a press conference in Zurich.
Business/Economics - Environment/Sustainable Development
22.02.2017
Reduction of energy consumption and CO2 emissions: promotion or steering?
Policy interventions to reduce energy consumption and CO2 emissions have a variety of effects on the economy and on households.
Business/Economics
13.02.2017
Financial windfall for young scientists
Financial windfall for young scientists
On February 2nd the EU approved Empa's «COFUND» application for financial support to the tune of more than ‘3.5 million, thereby securing partial funding for 50 post-doc positions at Empa over the next five years within the framework of the EU's Marie Sk'odowska-Curie actions.
Environment/Sustainable Development - Business/Economics
01.02.2017
User feedback is essential, especially for complex technology
User feedback is essential, especially for complex technology
Environmentally friendly, low-carbon energy technologies are needed to achieve global climate targets.
Business/Economics - Life Sciences
31.01.2017
In cold water
In cold water
Martin Ostermaier wanted to break out of the comfort zone of science. Now, instead of pipettes, the biochemist is dealing with investors and patent law.
Business/Economics - Administration/Government
31.01.2017
Opening doors in Asia
Opening doors in Asia
Both science and Swiss businesses are benefiting from the ETH science hub in Singapore. The newly founded Switzerland Technology Impact Platform (STIP) is helping Swiss SMEs to gain a foothold in Asia.
Business/Economics
30.01.2017
Towards better forecasts of slab avalanches
Towards better forecasts of slab avalanches
A team of researchers from EPFL and the SLF has developed a new model that describes how slab avalanches release.
Life Sciences - Business/Economics
30.01.2017
The Attraction Effect: how our Brains Can Be Influenced
The Attraction Effect: how our Brains Can Be Influenced
The decisions we make are influenced by other possibilities that we did not choose. At the same time, the options we missed out on determine our satisfaction with the outcomes of situations we were unable to control. Psychologists from the University of Basel conducted two experiments: first, they studied the decision-making behavior of students and, second, they measured brain activity and satisfaction when a set of possibilities is supplemented with another alternative.
Physics/Materials Science - Business/Economics
26.01.2017
‘Additive Manufacturing' speeds up
‘Additive Manufacturing’ speeds up
Empa offers Switzerland a platform to exchange information and knowhow in the field of Additive Manufacturing: During a technology briefing held at Empa Academy on January 18, experts from industry a
Medicine/Pharmacology - Business/Economics
26.01.2017
Inability to Work: Medical Experts Often Disagree
Independent medical evaluations are often used to adjudicate disability claims. But different doctors assessing the same patient often disagree on whether the patient is disabled or not. This problem can be mitigated by applying standardized procedures, says an international study led by researchers at the University of Basel and the University Hospital Basel in Switzerland.
Business/Economics - Medicine/Pharmacology
25.01.2017
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback FY net sales (0% cc ) in line with prior year due to st
Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Business/Economics
16.12.2016
Switzerland ratifies Croatia protocol
Bern, 16.12.2016 - Switzerland has ratified the protocol extending the free movement of persons to Croatia.
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Business/Economics - Careers/Employment
09.12.2016
Business/Economics - Astronomy
01.12.2016
President Schneider-Ammann attends ESA Ministerial Council
Bern, 01.12.2016 - On 1 December, President Johann N. Schneider-Ammann addressed the ministers of the 22 member states of the European Space Agency ESA and Canada in Lucerne.
Business/Economics - Computer Science/Telecom
01.12.2016
Swiss businesses are good process innovators
Swiss businesses are good process innovators
Switzerland's economy is facing some tough challenges: technologies are developing rapidly, processes are being amalgamated both inside and outside production facilities, and business units are becoming increasingly interconnected.
Medicine/Pharmacology - Business/Economics
29.11.2016
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100
Medicine/Pharmacology - Business/Economics
21.11.2016
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options   Results of SUSTAIN will be presented
Business/Economics
18.11.2016
Transitioning the publication system towards Open Access: Study proposes pragmatic scenario
Transitioning the publication system towards Open Access: Study proposes pragmatic scenario
For the first time, a study has developed scenarios for restructuring transitioning Switzerland's scientific publication system towards Open Access (OA). The study was initiated by the SNSF in collaboration with the Scientific Information programme (SUC P-2) run by swissuniversities. It recommends a model that proposes a pragmatic and flexible way of making publicly funded research freely available at no charge and with no delay.
Business/Economics
04.11.2016
Switzerland intensifies relations with Mexico
Bern, 04.11.2016 - President Johann N. Schneider-Ammann has paid a two-day presidential visit to Mexico.
Careers/Employment - Business/Economics
26.10.2016
A 10 million euro round of financing for the start up Coorpacademy
A 10 million euro round of financing for the start up Coorpacademy
Coorpacademy, a startup based in EPFL's Innovation Park, has completed a 10 million euro round of financing.
Business/Economics - Medicine/Pharmacology
25.10.2016
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters Q3 net sales (-1% cc and USD) broadly in line wit
1 2 3 4 5 8 Next »

 
 
Logo Careerjet